Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2023-11-13 00:00:00 ET · period of report 2023-11-13 · accession 0001209191-23-055083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-11-13 | 2023-11-13 | JANX | Avalon Ventures XI, L.P. | 10% | P - Purchase | $5.87 | +849.9K | 849.9K | New | +$4.99M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-13 | P | A | 849,854 | $5.87 | 849,854 | I See footnote | — | — | (F1) The shares are directly held by Avalon BioVentures I, LP (ABV I). Avalon BioVentures GP, LLC is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. Jay B. Lichter, Tighe M. Reardon, Sanford J. Madigan and Sergio G. Duron share voting and investment power with respect to the shares held by ABV I. Each of such individuals disclaims beneficial ownership of all shares held by ABV I except to the extent of each such individual's actual pecuniary interest therein, if any. |